<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mehra R</submitter><funding>NCI NIH HHS</funding><pagination>e2300565</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11569832</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Develop and validate gene expression-based biomarker associated with recurrent disease to facilitate risk stratification of clear cell renal cell carcinoma (ccRCC).&lt;h4>Materials and methods&lt;/h4>We retrospectively identified 110 patients who underwent radical nephrectomy for ccRCC (&lt;i>discovery&lt;/i> cohort). Patients who recurred were matched on the basis of grade/stage to patients without recurrence. Capture whole-transcriptome sequencing was performed on RNA isolated from archival tissue using the Illumina platform. We developed a gene-expression signature to predict recurrence-free survival/disease-free survival (DFS) using a 15-fold lasso and elastic-net regularized linear Cox model. We derived the 31-gene cell cycle progression (mxCCP) score using RNA-seq data for each p</pubmed_abstract><journal>JCO precision oncology</journal><pubmed_title>Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.</pubmed_title><pmcid>PMC11569832</pmcid><funding_grant_id>P30 CA046592</funding_grant_id><funding_grant_id>R37 CA283857</funding_grant_id><pubmed_authors>Nallandhighal S</pubmed_authors><pubmed_authors>Knuth Z</pubmed_authors><pubmed_authors>Su F</pubmed_authors><pubmed_authors>Cotta B</pubmed_authors><pubmed_authors>Kasputis A</pubmed_authors><pubmed_authors>Cao X</pubmed_authors><pubmed_authors>Wang R</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Cieslik MP</pubmed_authors><pubmed_authors>Salami SS</pubmed_authors><pubmed_authors>Mehra R</pubmed_authors><pubmed_authors>Udager AM</pubmed_authors><pubmed_authors>Dhanasekaran SM</pubmed_authors><pubmed_authors>Morgan TM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.</name><description>&lt;h4>Purpose&lt;/h4>Develop and validate gene expression-based biomarker associated with recurrent disease to facilitate risk stratification of clear cell renal cell carcinoma (ccRCC).&lt;h4>Materials and methods&lt;/h4>We retrospectively identified 110 patients who underwent radical nephrectomy for ccRCC (&lt;i>discovery&lt;/i> cohort). Patients who recurred were matched on the basis of grade/stage to patients without recurrence. Capture whole-transcriptome sequencing was performed on RNA isolated from archival tissue using the Illumina platform. We developed a gene-expression signature to predict recurrence-free survival/disease-free survival (DFS) using a 15-fold lasso and elastic-net regularized linear Cox model. We derived the 31-gene cell cycle progression (mxCCP) score using RNA-seq data for each p</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-02T20:43:30.377Z</modification><creation>2026-04-20T03:10:35.078Z</creation></dates><accession>S-EPMC11569832</accession><cross_references><pubmed>38810179</pubmed><doi>10.1200/PO.23.00565</doi><doi>10.1200/po.23.00565</doi></cross_references></HashMap>